Uncovering a novel mechanism whereby NK cells interfere with glioblastoma virotherapy

Oncoimmunology. 2013 Apr 1;2(4):e23658. doi: 10.4161/onci.23658.


Despite initial promising results, the success of clinical trials testing oncolytic viruses in glioblastoma patients has been limited. Innate immunity appears to be one among several barriers against successful viral oncolysis. Recent findings suggest a mechanism by which natural killer cells limit the efficacy of oncolytic viruses via natural cytotoxicity receptors.

Keywords: brain tumor; cancer; glioblastoma; innate immunity; oncolytic virus.